Planning Grant: I/UCRC for a New Site within the Center for Pharmaceutical Development

规划拨款：I/UCRC 在药物开发中心内建立新场地

• 批准号: 1338876
• 负责人: Christopher Roberts
• 金额: $ 1.46万
• 依托单位: University of Delaware
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-10-01 至 2014-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1338876&HistoricalAwards=false
• 关键词: Planning; Grant; UCRC; New; Site

The proposal requests funding for the University of Delaware (UDEL) to join the Center for Pharmaceutical Development (CPD). Georgia Tech at CPD is the lead institution, while the University of Kentucky Is a 'Partner' site. The proposed I/UCRC Site at the University of Delaware will bring world-class expertise to an existing Center for Pharmaceutical Development (CPD) in technical areas that are central to biopharmaceutical development innovation. These areas are currently absent or represent only a small portion of the expertise within the CPD, and will enable the CPD to build upon its strengths focused on development of small-molecule pharmaceuticals, industrial enzymes, and related biotechnology products; making the expanded CPD an even more robust and high-impact I/UCRC. The faculty in the proposed Site for the CPD are world-recognized leaders, and will provide new strengths to the current CPD that complements the existing expertise in solid-state pharmaceutical stability and delivery, and development of industrial enzymes and related biotechnology products. The proposed, expanded CPD will be the most far-reaching industry-university consortium to date that is focused on pharmaceutical product development, rather than discovery research or clinical development. The project areas it will address have the potential to greatly improve the efficiency and economics of drug development research and engineering, as well as the fundamental understanding and education of engineers and scientists in the industry. This can benefit the U.S. broadly in terms of domestic job creation, as well as improved time to market, cost to patients, and reduced risk for investors for the development and testing of new therapeutic proteins (focus of UD Site) and innovator pharmaceuticals more generally (focus of CPD overall). The PIs will involve students from underrepresented groups in science and engineering, including through research internships that are funded internally or through complementary federal funding.

该提案要求为特拉华大学 (UDEL) 提供资金以加入药物开发中心 (CPD)。佐治亚理工学院 CPD 是牵头机构，肯塔基大学是“合作伙伴”网站。拟议的特拉华大学 I/UCRC 站点将为现有的药物开发中心 (CPD) 带来生物制药开发创新核心技术领域的世界一流专业知识。这些领域目前缺乏或只代表 CPD 专业知识的一小部分，将使 CPD 能够发挥其专注于小分子药物、工业酶和相关生物技术产品开发的优势；使扩展后的 CPD 成为更加强大和高影响力的 I/UCRC。拟议的 CPD 地点的教师都是世界公认的领导者，他们将为当前的 CPD 提供新的优势，补充固态药物稳定性和输送以及工业酶和相关生物技术产品开发方面的现有专业知识。拟议的扩大的 CPD 将成为迄今为止影响最深远的工业大学联盟，专注于药品开发，而不是发现研究或临床开发。它将涉及的项目领域有可能大大提高药物开发研究和工程的效率和经济性，以及行业工程师和科学家的基本理解和教育。这可以使美国在创造国内就业机会、缩短上市时间、降低患者成本以及降低投资者开发和测试新治疗蛋白（UD 网站的焦点）和更广泛的创新药物方面的风险方面广泛受益。 （CPD 整体重点）。 PI 将让来自科学和工程领域代表性不足群体的学生参与进来，包括通过内部资助或补充性联邦资助进行研究实习。